Vascular Biogenics Raises $15M In Stock Offering

November 8, 2015 | Israeli bio-med company Vascular Biogenics raised $15 million following the closure of its stock offering of 2,500,000 ordinary shares at $6.00 per share. The company intends to use the net proceeds from the offering for the advancement of clinical programs, and for working capital. Founded in 2000 by CEO Prof. Dror Harats, Vascular Biogenics is a late-stage clinical bio-pharmaceutical company focused on the discovery, development and commercialization of gene-based treatments for cancer, including their lead drug, VB-111 that is being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer.